Methyl-CpG-binding domain 2: a protective role in bladder carcinoma.

摘要: BACKGROUND MBD2, a methyl-CpG-binding domain 2 protein, has attracted much attention because of its role in epigenetic regulation gene expression. In addition to transcriptional repression, MBD2 also been shown catalyze demethylation by directly removing methyl groups from 5-methylcytosine residues DNA. Although the demethylase activity remains controversial, reduction messenger RNA expression observed various tumor tissue types. current case–control study, authors investigated association between and bladder carcinoma risk. METHODS RNA was isolated peripheral blood lymphocytes 98 case patients 135 frequency-matched control patients. measured real-time quantitative reverse transcription–polymerase chain reaction assays. RESULTS Overall, there significantly reduced risk associated with high levels (odds ratio [OR], 0.43; 95% confidence interval [CI], 0.21–0.90). This relation maintained when data were categorized according quartile distribution for (P trend < 0.05). It is noteworthy that protective effects more apparent women (OR, 0.25; CI, 0.06–1.02) compared men 0.58; 95%; 0.24–1.42), older individuals 0.12; 0.03–0.45) younger 1.16; 0.40–3.33), heavier smokers 0.40; 0.18–0.93) lighter 0.71; 0.18–2.86). CONCLUSIONS Although underlying molecular mechanisms remain unclear, obtained study represent first evidence demonstrating against MBD2. may prevent age-related, gender-related, smoking-induced hypermethylation, which are predisposing factors development. Cancer 2004. © 2004 American Society.